Tuberculosis echocardiography or ultrasound
|
Tuberculosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Drug-Susceptible and Drug-Resistant Tuberculosis(ATS 2025 Guidelines) |
|
Case Studies |
|
Tuberculosis echocardiography or ultrasound On the Web |
|
American Roentgen Ray Society Images of Tuberculosis echocardiography or ultrasound |
|
Risk calculators and risk factors for Tuberculosis echocardiography or ultrasound |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mashal Awais, M.D.[2];Sophia Saad, Associate Editor - WikiDoc [3] Ammu Susheela, M.D. [4]
Echocardiography or ultrasound
Overview
Echocardiography and ultrasound evaluate cardiac and related involvement in tuberculosis. The pericardium is the most commonly affected cardiac structure. Pericardial involvement (effusion, pericarditis, or constriction) occurs in 2–5% of TB cases and at higher rates in patients with HIV coinfection.[1][2] In HIV-positive patients with pericardial effusion in endemic settings, tuberculosis is the cause in over 80% of cases, making TB the default diagnostic consideration in this population.[3] Myocardial TB (<2%), endocarditis (<1%), and aortitis (<1%) are rare.[1]
Transthoracic echocardiography (TTE) is first-line for detecting and monitoring pericardial effusion, assessing for tamponade, identifying constrictive physiology, and evaluating myocardial involvement.[4][5]
A 2025 prospective study from Southern Africa found echocardiographic pericardial abnormalities in 66% of newly diagnosed TB patients, including pericardial effusion in 47% and signs of constriction in 42%, indicating a higher burden of subclinical cardiac involvement than previously recognized.[6]
Echocardiographic findings in tuberculous pericardial effusion
TB is the most common cause of pericardial effusion and the leading cause of constrictive pericarditis in endemic areas.[4][5] In North America and Western Europe, TB-related pericardial disease is less common but should be considered in at-risk populations (immigrants from endemic areas, HIV-positive patients).[4]
The 2025 ACC Expert Consensus Statement recommends TTE as the first-line investigation for pericardial effusions. Sizing criteria based on the greatest end-diastolic diameter perpendicular to the epicardium are:[4]
- Trivial: <1.0 cm, not visualized throughout the cardiac cycle
- Small: <1.0 cm
- Moderate: 1.0–1.9 cm
- Large: 2.0–2.5 cm
- Very large: >2.5 cm
Features suggestive of tuberculous pericardial effusion (versus idiopathic or other causes) include:[7]
- Exudative/complex effusion (echogenic, heterogeneous fluid ± loculations, stranding, or adhesions; sensitivity 65.2% for TB etiology)
- Fibrin strands protruding from or crossing the pericardial space
- Pericardial thickening (specificity 76.9% for TB etiology)
- Echo-dense deposits around the epicardium
Echocardiographic features alone do not significantly differ across etiologies of pericardial effusion and cannot definitively distinguish TB from other causes.[7] Definitive diagnosis requires isolation of Mycobacterium tuberculosis from pericardial fluid or tissue, or supportive evidence such as pericardial fluid adenosine deaminase (ADA) level. A threshold of 40 U/L is most commonly used (sensitivity 88%, specificity 83% in meta-analysis), though some studies have used lower cutoffs (e.g., 30 U/L with higher sensitivity). The ATS/IDSA/CDC 2017 guideline conditionally recommends ADA measurement in pericardial fluid (conditional recommendation, low-quality evidence).[1][7][8][9] The ATS/IDSA/CDC 2017 guideline does not recommend measurement of free interferon-gamma (IFN-γ) in pericardial fluid due to insufficient data, unlike in pleural and peritoneal fluid where it is conditionally recommended.[8]
The presence of pleural effusion in a patient with pulmonary TB is strongly associated with concurrent tuberculous pericardial effusion (OR 24.4 in one single-center study) and should prompt echocardiographic evaluation.[10]
Echocardiographic assessment of cardiac tamponade
TB pericardial effusions may progress to cardiac tamponade, particularly in HIV-coinfected patients. Hemodynamic impact depends more on the rapidity of fluid accumulation than absolute volume.[4][5]
Key echocardiographic findings of tamponade include:[4][11]
- Dilated IVC (>2.1 cm) with minimal respiratory variation (high-sensitivity screening sign; does not confirm tamponade)
- Diastolic right ventricular collapse (most specific finding)
- Right atrial inversion exceeding one-third of the cardiac cycle
- Respiratory variation in ventricular inflow (transmitral >30%, transtricuspid >60%)
- Respirophasic ventricular interdependence (septal shift)
- Small left ventricular end-diastolic and end-systolic volumes
Echocardiography-guided pericardiocentesis is recommended for impending or established tamponade and for diagnostic purposes when TB is suspected.[4]
Echocardiographic features of constrictive pericarditis
TB is the most common cause of constrictive pericarditis in endemic areas.[4] Constrictive physiology results from loss of pericardial elasticity impairing diastolic ventricular filling. A critical distinction exists between chronic constrictive pericarditis (irreversible fibrosis, usually requiring pericardiectomy) and transient constrictive pericarditis (inflammation-driven; may resolve with anti-TB therapy ± corticosteroids over 3–6 months).[4]
Echocardiographic hallmarks of constrictive physiology include:[4]
- Interventricular septal shift to the left with inspiration (respirophasic septal bounce)
- E-wave predominant mitral inflow pattern
- Elevated mitral annular e' velocities (paradoxically preserved or elevated despite diastolic dysfunction)
- Annulus reversus (medial e' velocity exceeding lateral e' velocity)
- Plethoric IVC with minimal respiratory variation
- Late-diastolic expiratory flow reversal in hepatic veins
- Respirophasic variation in mitral and tricuspid inflow velocities
No single echocardiographic criterion is diagnostic of constriction; the diagnosis requires integration of multiple findings, and clinical context remains essential.[4] Echocardiography may occasionally detect pericardial calcification as bright, echo-dense structures with acoustic shadowing, though cardiac CT is more sensitive for this finding.[4][11]
Effusive constrictive pericarditis (persistent constrictive pathophysiology after drainage of a pericardial effusion) is a distinct entity in TB and reflects marked visceral pericardial inflammation.[4][5]
Response to anti-TB treatment and serial monitoring
Early inflammatory changes (pericardial effusion, pericardial thickening) regress significantly with 6 months of anti-TB therapy, while established constrictive disease persists despite treatment.[6] This underscores the importance of early detection.
Serial TTE is reasonable for surveillance of at least moderate-sized pericardial effusions, typically at 1–4 week intervals depending on clinical stability and hemodynamic status.[4] Cardiac magnetic resonance (CMR) should be considered when echocardiography is equivocal for constriction or when assessing pericardial inflammation and treatment response.[4]
Myocardial tuberculosis
Myocardial TB is rare (<2% of cardiac TB) and may present as:[1][12]
- Cardiac tuberculoma (intracardiac mass, most commonly in the right heart chambers; often misdiagnosed as a cardiac tumor)
- Restrictive or dilated cardiomyopathy with global hypokinesia, chamber enlargement, and valvular regurgitation
- Left ventricular systolic dysfunction
When an intracardiac mass is identified on echocardiography in a patient with known TB, myocardial tuberculoma should be considered in the differential alongside primary cardiac tumors and metastases. CMR provides superior tissue characterization (T2 hypointensity (low signal on T2-weighted sequences, reflecting caseous necrosis and fibrosis) is characteristic of tuberculomas).[12]
In one endemic cohort, LV systolic dysfunction was found in only 1% of newly diagnosed TB patients, and significant valvular regurgitation was similarly uncommon (≤1% for each valve).[6]
Complementary imaging modalities
Per the 2025 ACC Expert Consensus Statement:[4]
- TTE is first-line for all suspected pericardial disease
- CMR is second-line, especially for assessing pericardial inflammation (late gadolinium enhancement, T2 edema), distinguishing transient from chronic constriction, and evaluating myocardial involvement
- Cardiac CT is preferred for detecting pericardial calcifications in chronic constrictive pericarditis and for preoperative planning before pericardiectomy
- Transesophageal echocardiography and stress echocardiography are generally not required
High-yield clinical pearls
- TB is the leading cause of pericardial effusion and constrictive pericarditis in endemic areas.[4]
- Fibrin strands, pericardial thickening, and exudative fluid raise suspicion for TB etiology but are not diagnostic alone.[7]
- Coexisting pleural effusion in pulmonary TB confers markedly increased odds of concurrent pericardial effusion; perform TTE.[10]
- Diastolic right ventricular collapse is the most specific echocardiographic sign of tamponade; dilated IVC is the most sensitive screening sign.[4]
- Annulus reversus (medial > lateral e') and paradoxically elevated mitral annular e' velocities help distinguish constrictive pericarditis from restrictive cardiomyopathy on tissue Doppler.[4]
- Pericardial effusion and thickening regress with anti-TB treatment; established constriction does not.[6]
Common pitfalls
- Mistaking a left pleural effusion for a pericardial effusion: pericardial fluid tracks anterior to the descending aorta on parasternal long-axis view; pleural fluid tracks posterior.[4][11]
- Epicardial fat pad mimicking effusion: fat appears heterogeneously echogenic and moves with the myocardium.[4]
- Assuming echocardiographic findings alone confirm TB etiology: features do not significantly differ across causes; microbiologic or biochemical confirmation is required.[7]
- Missing effusive constrictive pericarditis: constrictive physiology may become apparent only after pericardiocentesis.[4]
- Diagnosing myocardial tuberculoma as a cardiac tumor: consider TB in patients with known TB or from endemic areas who have intracardiac masses, especially in the right heart.[12]
References
- ↑ 1.0 1.1 1.2 1.3 Farina JM, Liblik K, Iomini P; et al. (2023). "Infections and Cardiovascular Disease: JACC Focus Seminar 1/4". Journal of the American College of Cardiology. 81 (1): 71–80. doi:10.1016/j.jacc.2022.08.813.
- ↑ López-López JP, Posada-Martínez EL, Saldarriaga C; et al. (2021). "Tuberculosis and the Heart". Journal of the American Heart Association. 10 (7): e019435. doi:10.1161/JAHA.120.019435.
- ↑ Wiysonge CS, Ntsekhe M, Thabane L; et al. (2017). "Interventions for Treating Tuberculous Pericarditis". The Cochrane Database of Systematic Reviews. 9: CD000526. doi:10.1002/14651858.CD000526.pub2.
- ↑ 4.00 4.01 4.02 4.03 4.04 4.05 4.06 4.07 4.08 4.09 4.10 4.11 4.12 4.13 4.14 4.15 4.16 4.17 4.18 4.19 4.20 4.21 Wang TKM, Klein AL, Cremer PC; et al. (2025). "2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Diagnosis and Management of Pericarditis". Journal of the American College of Cardiology. 86 (25): 2691–2719. doi:10.1016/j.jacc.2025.05.023.
- ↑ 5.0 5.1 5.2 5.3 Cremer PC, Klein AL, Imazio M (2024). "Diagnosis, Risk Stratification, and Treatment of Pericarditis". JAMA. 332 (13): 1090–1100. doi:10.1001/jama.2024.12935.
- ↑ 6.0 6.1 6.2 6.3 Samim D, Muula G, Banholzer N; et al. (2025). "Cardiovascular Involvement in Tuberculosis Patients Treated in Southern Africa". JACC Advances. 4 (1): 101427. doi:10.1016/j.jacadv.2024.101427.
- ↑ 7.0 7.1 7.2 7.3 7.4 Shaik NJ, Hegde SS, Seshadri S, Cherukuri M (2024). "Pericardial Effusion in an Indian Context: Clinical Insights and Dynamics From a Tertiary Care Centre". BMC Cardiovascular Disorders. 24 (1): 714. doi:10.1186/s12872-024-04381-1.
- ↑ 8.0 8.1 Lewinsohn DM, Leonard MK, LoBue PA; et al. (2017). "Official ATS/IDSA/CDC Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children". Clinical Infectious Diseases. 64 (2): e1–e33. doi:10.1093/cid/ciw694.
- ↑ Burgess LJ, Reuter H, Carstens ME, Taljaard JJ, Doubell AF (2002). "The Use of Adenosine Deaminase and Interferon-Gamma as Diagnostic Tools for Tuberculous Pericarditis". Chest. 122 (3): 900–905. doi:10.1378/chest.122.3.900.
- ↑ 10.0 10.1 Casas E, Blanco JR, Ibarra V; et al. (2000). "Incidence of Pericardial Effusion in Pulmonary Tuberculosis". The International Journal of Tuberculosis and Lung Disease. 4 (12): 1173–5.
- ↑ 11.0 11.1 11.2 Chiabrando JG, Bonaventura A, Vecchié A; et al. (2020). "Management of Acute and Recurrent Pericarditis: JACC State-of-the-Art Review". Journal of the American College of Cardiology. 75 (1): 76–92. doi:10.1016/j.jacc.2019.11.021.
- ↑ 12.0 12.1 12.2 Xie A, Yuan S, Yu S (2026). "Right Ventricular Myocardial Tuberculosis Misdiagnosed as a Cardiac Tumor". Journal of Clinical Ultrasound. 54 (6): 1493–1496. doi:10.1002/jcu.70202.